Aminocaproic acid (aminocaproic acid) 5% 100 ml.

Description

Ingredients

active substance: aminocaproic acid;

• 100 ml of solution contain 5 g of aminocaproic acid;

excipients: sodium chloride, water for injections.

Medicinal form

Solution for infusions.

Pharmacotherapeutic group

Antihemorrhagic agents. Inhibitors of fibrinolysis.

ATX code B02A A01.

Pharmacodynamics

Aminocaproic acid solution has a hemostatic, antifibrinolytic effect in bleeding caused by increased fibrinolysis. Its action is associated with the blockade of plasminogen activators and partial inhibition of the effect of plasmin. The drug also inhibits biogenic polypeptides – kinins. Contributes to the stabilization of fibrin and its deposition in the vascular bed, induces the aggregation of platelets and erythrocytes.

Aminocaproic acid has an anti-allergic, antiviral effect, enhances the detoxifying function of the liver. Inhibits proteolytic activity associated with the influenza virus. Aminocaproic acid has an inhibitory effect on the early stages of the interaction of the virus with sensitive cells, and also suppresses the proteolytic processing of hemagglutinin. As a result, the functionally active protein of the influenza virus, which ensures its infectious activity, is not created, and the amount of daughter infectious virus decreases. Aminocaproic acid not only shows antiviral activity, but also improves some cellular and humoral indicators of specific and nonspecific protection of the body during respiratory viral infections.

Indications

• Bleeding after surgical operations and various pathological conditions associated with increased fibrinolytic activity of blood and tissues.
• Prevention of the development of secondary hypofibrinogenemia during massive transfusions of preserved blood.
• Treatment and prevention of influenza and SARS in children and adults.

Contraindications

• Increased sensitivity to the components of the medicinal product;
• tendency to thrombosis and thromboembolic diseases, thromboembolism;
• coagulopathy due to diffuse intravascular blood coagulation;
• kidney disease with impaired kidney function, kidney failure, hematuria;
• the period of pregnancy, childbirth, breastfeeding;
• severe form of coronary heart disease;
• violation of cerebral circulation.

Directions

“Aminocaproic acid” solution should be administered orally or intravenously.

Adults are prescribed 5 g (100 ml) of the drug orally. Then 1 g (20 ml) every hour for 8 hours until the bleeding stops completely.

If it is necessary to achieve a quick effect (acute hypofibrinogenemia), administer intravenously by drop to 100 ml of solution (5 g) at a rate of 50–60 drops per minute for 15–30 minutes. During the first hour, enter in a dose of 4-5 g, and in the case of prolonged bleeding – until its complete stop – enter 1 g every hour, but no more than 8 hours.

In case of repeated bleeding, repeat the administration of the 5% solution.

Children.

With a moderate increase in fibrinolytic activity, “Aminocaproic acid” should be prescribed to children at a dose of 0.05 g/kg of body weight once a day. The dose depending on age is:

• children under 1 year of age: one time — up to 2.5 ml; daily — 15 ml;
• from 2 to 6 years: single — 2.5–5 ml; daily — 15–30 ml;
• from 7 to 10 years: one time — 5–7 ml; daily — 30–45 ml;
• from 11 to 18 years: single dose — 7–14 ml; daily — 45–90 ml.

For acute bleeding, the doses are:

• children under 1 year of age: one time — 5 ml; daily — 30 ml;
• from 2 to 4 years: one time — 5–7.5 ml; daily — 30–45 ml;
• from 5 to 8 years: one-time — 7.5–10 ml; daily — 45–60 ml;
• from 9 to 10 years: one time — 15 ml; daily — 90 ml;
• from 11 to 14 years: one time — 20 ml; daily — 120 ml;
• from 15 to 18 years: one-time — 28 ml; per day – 160 ml.

The course of treatment is from 3 to 14 days.

For the prevention and treatment of influenza and SARS, the drug should be used orally and topically (0.5–1 ml in the nose 3–4 times a day).

The drug should be prescribed orally to children in doses:

• children under 2 years old — 1–2 g (20–40 ml of 5% solution per day) — 1–2 teaspoons 4 times a day (0.02–0.04 g/kg — a single dose), can be added to food or drinks;
• children aged 2 to 6 years — 2–4 g (40–80 ml of 5% solution per day) — 1–2 tablespoons 4 times a day;
• children aged 7 years and older and adults — 4–5 g (80–100 ml of 5% solution per day), dividing the daily dose into 4 doses.

For more accurate dosing of the solution, it is advisable to use a medical syringe without a needle with a volume of 10 or 20 ml.

At the same time, the local application of aminocaproic acid is justified. It is recommended to insert cotton swabs moistened with 5% aminocaproic acid solution into the nasal passages for 5–10 minutes every 3–4 hours, or to instill 3–5 drops of the solution into each nasal passage at the specified times.

If necessary, aminocaproic acid can be used in combination with other antiviral drugs and interferon and its inducers.

Intranasal instillations of aminocaproic acid (3-4 times a day) should be carried out during the epidemic period in order to prevent influenza, which should be supplemented with enteral (as in treatment) application of the drug in foci of infection when in contact with the patient.

The duration of oral administration of aminocaproic acid for influenza and SARS is 3–7 days.

The duration of treatment depends on the severity of the disease and is determined by the doctor individually. The doctor can also adjust the dose and prescribe a repeat course of treatment.